JonesTrading analyst Sean Kim initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Buy rating and announces Price Target of $7.
Morgan Stanley Downgrades Five9 to Equal-Weight
Morgan Stanley analyst Meta Marshall downgrades Five9 (NASDAQ:FIVN) from Overweight to Equal-Weight.